File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma

TitlePhase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma
Authors
KeywordsDistant metastases
Epidermal growth factor receptor
Gefitinib
Nasopharyngeal carcinoma
Recurrence
Issue Date2008
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/38137
Citation
Head And Neck, 2008, v. 30 n. 7, p. 863-867 How to Cite?
AbstractBackground. This single-center, phase II study assessed the safety/tolerability and initial efficacy of gefitinib in patients with nasopharyngeal carcinoma (NPC) pretreated with platinum-based chemotherapy. Methods. Patients with recurrent and metastatic NPC who had treatment failure with at least 2 lines of chemotherapy including platinum were given gefitinib at a fixed dose of 250 mg daily. Treatment was continued until the patient experienced unacceptable side effects or disease progression. Results. Nineteen patients were enrolled, having had treatment failure with a median of 2 chemotherapy regimens. Treatment was well tolerated, and only grades 1 to 2 adverse events were observed. None of the patients achieved partial or complete response. Median time-to-progression was 4 months, and median overall survival was 16 months. Conclusion. Gefitinib was well tolerated, but the response rate was poor in this heavily pretreated study population, and its use in NPC is not recommended outside the context of clinical trial. ©2008 Wiley Periodicals, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/58618
ISSN
2015 Impact Factor: 2.76
2015 SCImago Journal Rankings: 1.233
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChua, DTTen_HK
dc.contributor.authorWei, WIen_HK
dc.contributor.authorWong, MPen_HK
dc.contributor.authorSham, JSTen_HK
dc.contributor.authorNicholls, Jen_HK
dc.contributor.authorGordon, KHen_HK
dc.date.accessioned2010-05-31T03:33:37Z-
dc.date.available2010-05-31T03:33:37Z-
dc.date.issued2008en_HK
dc.identifier.citationHead And Neck, 2008, v. 30 n. 7, p. 863-867en_HK
dc.identifier.issn1043-3074en_HK
dc.identifier.urihttp://hdl.handle.net/10722/58618-
dc.description.abstractBackground. This single-center, phase II study assessed the safety/tolerability and initial efficacy of gefitinib in patients with nasopharyngeal carcinoma (NPC) pretreated with platinum-based chemotherapy. Methods. Patients with recurrent and metastatic NPC who had treatment failure with at least 2 lines of chemotherapy including platinum were given gefitinib at a fixed dose of 250 mg daily. Treatment was continued until the patient experienced unacceptable side effects or disease progression. Results. Nineteen patients were enrolled, having had treatment failure with a median of 2 chemotherapy regimens. Treatment was well tolerated, and only grades 1 to 2 adverse events were observed. None of the patients achieved partial or complete response. Median time-to-progression was 4 months, and median overall survival was 16 months. Conclusion. Gefitinib was well tolerated, but the response rate was poor in this heavily pretreated study population, and its use in NPC is not recommended outside the context of clinical trial. ©2008 Wiley Periodicals, Inc.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/38137en_HK
dc.relation.ispartofHead and Necken_HK
dc.rightsHead & Neck. Copyright © John Wiley & Sons, Inc.en_HK
dc.subjectDistant metastasesen_HK
dc.subjectEpidermal growth factor receptoren_HK
dc.subjectGefitiniben_HK
dc.subjectNasopharyngeal carcinomaen_HK
dc.subjectRecurrenceen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - administration & dosage - adverse effectsen_HK
dc.subject.meshCarcinoma, Squamous Cell - drug therapy - mortality - secondaryen_HK
dc.subject.meshDose-Response Relationship, Drugen_HK
dc.subject.meshDrug Administration Scheduleen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshFollow-Up Studiesen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMaximum Tolerated Doseen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshNasopharyngeal Neoplasms - drug therapy - mortality - pathologyen_HK
dc.subject.meshNeoplasm Metastasisen_HK
dc.subject.meshNeoplasm Recurrence, Local - drug therapy - mortality - pathologyen_HK
dc.subject.meshNeoplasm Stagingen_HK
dc.subject.meshQuinazolines - administration & dosage - adverse effectsen_HK
dc.subject.meshRisk Assessmenten_HK
dc.subject.meshSurvival Analysisen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titlePhase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1043-3074&volume=30&issue=7&spage=863&epage=7&date=2008&atitle=Phase+II+study+of+gefitinib+for+the+treatment+of+recurrent+and+metastatic+nasopharyngeal+carcinomaen_HK
dc.identifier.emailChua, DTT: dttchua@hkucc.hku.hken_HK
dc.identifier.emailWei, WI: hrmswwi@hku.hken_HK
dc.identifier.emailWong, MP: mwpik@hkucc.hku.hken_HK
dc.identifier.emailNicholls, J: jmnichol@hkucc.hku.hken_HK
dc.identifier.authorityChua, DTT=rp00415en_HK
dc.identifier.authorityWei, WI=rp00323en_HK
dc.identifier.authorityWong, MP=rp00348en_HK
dc.identifier.authorityNicholls, J=rp00364en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/hed.20792en_HK
dc.identifier.pmid18213730-
dc.identifier.scopuseid_2-s2.0-47549095907en_HK
dc.identifier.hkuros147217en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-47549095907&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume30en_HK
dc.identifier.issue7en_HK
dc.identifier.spage863en_HK
dc.identifier.epage867en_HK
dc.identifier.isiWOS:000257480700006-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridChua, DTT=7006773480en_HK
dc.identifier.scopusauthoridWei, WI=7403321552en_HK
dc.identifier.scopusauthoridWong, MP=7403907887en_HK
dc.identifier.scopusauthoridSham, JST=24472255400en_HK
dc.identifier.scopusauthoridNicholls, J=7201463077en_HK
dc.identifier.scopusauthoridGordon, KH=24522158500en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats